THE Pfizer reviewed today upwards its forecasts for sales of vaccine against Covid-19 for the full year by 7.5% to $ 36 billion, as it signs agreements with countries for booster doses and receives approvals for their use vaccines in older age groups.
The company also announced that it is on track to deliver 2.3 billion doses of vaccines, up from about 3 billion it plans to make this year.
In an unprecedented immunization effort against the COVID-19 pandemic worldwide, the vaccine Pfizer it happened quickly one of the best-selling products in the 172 years of the company’s history. The company shares equally the costs and benefits of the vaccine with its German partner, BioNTech.
Other competing companies, such as Modern and the Johnson & Johnson, According to the Athenian-Macedonian News Agency, they have encountered production problems, which has helped Pfizer expand its lead in signing supply agreements with various countries.
Pfizer is also releasing booster doses of the vaccine while awaiting the outcome of a meeting of US regulators later today on the use of its vaccine in children aged 5-11.
The vaccine grossed $ 13 billion in sales in the third quarter, with analysts expecting an average of $ 10.88 billion, according to a Refinitiv survey.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
